VANDA PHARMACEUTICALS INC's ticker is VNDA and the CUSIP is 921659108. A total of 168 filers reported holding VANDA PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 3.79 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $335,266 | -2.9% | 50,875 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $345,441 | -8.1% | 50,875 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $375,966 | -28.4% | 50,875 | -4.2% | 0.00% | -25.0% |
| Q3 2022 | $525,000 | -57.0% | 53,110 | -50.8% | 0.00% | -42.9% |
| Q1 2022 | $1,221,000 | -27.9% | 107,985 | 0.0% | 0.01% | -30.0% |
| Q4 2021 | $1,694,000 | -8.5% | 107,985 | 0.0% | 0.01% | -37.5% |
| Q3 2021 | $1,851,000 | -20.3% | 107,985 | 0.0% | 0.02% | -15.8% |
| Q2 2021 | $2,323,000 | +43.2% | 107,985 | 0.0% | 0.02% | +35.7% |
| Q1 2021 | $1,622,000 | +101.5% | 107,985 | +76.2% | 0.01% | +100.0% |
| Q4 2020 | $805,000 | +160.5% | 61,300 | +91.6% | 0.01% | +133.3% |
| Q3 2020 | $309,000 | -53.3% | 32,000 | -20.6% | 0.00% | -50.0% |
| Q4 2019 | $661,000 | -29.8% | 40,300 | -43.2% | 0.01% | -33.3% |
| Q3 2019 | $942,000 | – | 70,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 1,532,000 | $27,423,000 | 3.23% |
| Stonepine Capital Management, LLC | 300,000 | $5,370,000 | 3.16% |
| Palo Alto Investors LP | 4,155,670 | $74,386,000 | 3.13% |
| GREAT POINT PARTNERS LLC | 497,531 | $8,906,000 | 1.73% |
| Avoro Capital Advisors LLC | 988,270 | $17,690,000 | 1.37% |
| UNIVERSITY OF NOTRE DAME DU LAC | 157,781 | $2,824,000 | 0.79% |
| Birchview Capital, LP | 68,000 | $1,217,000 | 0.63% |
| Cheyne Capital Management (UK) LLP | 74,000 | $1,323,000 | 0.48% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 352,604 | $6,311,000 | 0.43% |
| 361 CAPITAL LLC | 119,554 | $2,140,000 | 0.41% |